Lexicon Pharmaceuticals Up 7% After EU Approval for Diabetes Treatment
April 29 2019 - 11:40AM
Dow Jones News
By Michael Dabaie
Lexicon Pharmaceuticals Inc. (LXRX) was up 7.2% to $6.39 in
heavier-than-average trading Monday.
The company said Friday that the European Commission granted
marketing authorization for Zynquista, which was developed by
Sanofi (SNY) and Lexicon. Zynquista is now approved in the European
Union for treatment of adults with type 1 diabetes.
Lexicon said Zynquista also is currently being evaluated in a
program of 11 clinical trials in adults with type 2 diabetes,
including two trials in people living with type 2 diabetes and
renal impairment, and two large cardiovascular outcomes trials.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 29, 2019 11:25 ET (15:25 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024
